Drug intelligence / Profile preview

Numeta G16%E

Development stage: Unknown
Lead developer: Baxter
Modality: Small Molecules
Administration: Intravenous

Overview

Numeta G16%E is a standardized, triple-chamber parenteral nutrition (PN) solution developed by Baxter, specifically designed for the nutritional support of preterm infants. The product contains a balanced mixture of amino acids, glucose, and electrolytes (including sodium, potassium, magnesium, calcium, and phosphate) in separate compartments that are mixed just prior to administration. This formulation is intended to meet the high metabolic and growth demands of premature neonates while reducing the risks associated with manual compounding, such as contamination and dosing errors. It is administered via intravenous infusion when enteral nutrition is impossible, insufficient, or contraindicated.

Brand names: Numeta G16%ENumeta G16E
Other names: Numeta G16%E with electrolytesParenteral nutrition for preterm infants

Beyond the preview

Go deeper on Numeta G16%E.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Numeta G16%E.